

**MARKET RELEASE**

**Release of shares from voluntary escrow**

**Melbourne, Australia, 17 March, 2021** - In accordance with Listing Rule 3.10A, MedAdvisor Limited (ASX: MDR) (**MedAdvisor**) advises that 15,008,943 fully paid ordinary shares currently held under voluntary escrow will be released from escrow on 31 March 2021. All of these shares are held by Wavey Industries Pty Ltd, a company associated with Mr Joshua Swinnerton, executive director of MedAdvisor.

Following the release of these shares from escrow, no shares in MedAdvisor will be subject to escrow.

Mr Swinnerton currently lives and works in Massachusetts, where he and his family have been located since late 2018 to support MedAdvisor's expansion efforts in the USA. This has allowed him to act as the key connector between the recently acquired Adheris business and MedAdvisor's Melbourne head office. Mr Swinnerton has assisted in the rapid and effective transition of Adheris from Syneos Health to MedAdvisor, and coordinates collaborative technical and product initiatives between the two branches of the business.

He is dedicated to realising the collaborative potential of combining the MedAdvisor and Adheris businesses.

Mr Swinnerton has informed the company that he does not have any current intention of disposing of his shares in the near future.

- ENDS -

*This document has been authorised for release by Naomi Lawrie, MedAdvisor Company Secretary.*

**For more information:**

Simon Glover  
Chief Financial Officer  
[corporate@medadvisor.com.au](mailto:corporate@medadvisor.com.au)  
+61 3 9095 3036

Alex Beashel  
Corporate Communications  
[ab@alexbeashel.com](mailto:ab@alexbeashel.com)  
+61 466 308 667

## **About MedAdvisor**

*MedAdvisor is a world-class medication management platform that empowers users to more simply manage their medication and improve adherence. MedAdvisor's highly automated and intuitive software system connects users to tools and education materials from their local/preferred pharmacy. In Australia, MedAdvisor has connected over 1.6 million users through more than 60% of Australian pharmacies and a network of thousands of GPs. MedAdvisor has recently partnered with HMS in the US, Zuellig Pharma in Asia and launched into the UK on track to become one of the largest players in the global digital adherence market. In 2018 and 2020, MedAdvisor was recognised in the AFR Fast 100. Visit: [mymedadvisor.com/investors](https://mymedadvisor.com/investors)*